• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Arrowhead Pharmaceuticals (ARWR)

Common Shares
Sell: $13.65|Buy: $13.88|Change: 0.42 (3.12%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Address

177 East Colorado Boulevard
Suite 700
Pasadena
CA
USA
91105

Telephone

+1 646 304-3400

Website

https://www.arrowheadpharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Arrowhead Pharmaceuticals Inc Annual General Meeting for 20252026-03-12T10:00:00
Arrowhead Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-02-10T16:30:00
Arrowhead Pharmaceuticals Inc First Quarter Earnings Results for 20262026-02-10T00:00:00
Arrowhead Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252025-11-26T16:30:00
Arrowhead Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252025-11-26T00:00:00
Arrowhead Pharmaceuticals Inc Annual Report for 20252025-11-26T00:00:00
Arrowhead Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-08-08T16:30:00
Arrowhead Pharmaceuticals Inc Third Quarter Earnings Results for 20252025-08-08T00:00:00
Arrowhead Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-05-09T16:30:00
Arrowhead Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-05-09T00:00:00

Previous key dates

NameKey Date
Arrowhead Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-05-09T16:30:00
Arrowhead Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-05-09T00:00:00
Arrowhead Pharmaceuticals Inc Annual General Meeting for 20242025-03-12T10:00:00
TD Cowen 45th Annual Health Care Conference2025-03-03T09:50:00
Arrowhead Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-02-10T16:30:00
Arrowhead Pharmaceuticals Inc First Quarter Earnings Result for 20252025-02-10T00:00:00
7th Annual Evercore ISI HealthCONx Conference2024-12-04T14:10:00
Piper Sandler 36th Annual Healthcare Conference2024-12-03T13:30:00
Arrowhead Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242024-11-26T16:30:00
Arrowhead Pharmaceuticals Inc Fourth Quarter Earnings Result for 20242024-11-26T00:00:00
Arrowhead Pharmaceuticals Inc Annual Report for 20242024-11-26T00:00:00
Arrowhead Pharmaceuticals Inc Jefferies London Healthcare Conference 20242024-11-20T08:00:00
Arrowhead Pharmaceuticals Inc UBS Global Healthcare Conference 20242024-11-12T15:30:00
Arrowhead Pharmaceuticals Inc. will participate 2024 Summer Series R&D Webinar: Central Nervous System – Platform and pipeline updates2024-10-07T16:30:00
2024 Cantor Fitzgerald Global Healthcare Conference2024-09-17T08:35:00
Investor Conference Call on Plozasiran PALISADE Results from ESC 20242024-09-03T08:00:00
Arrowhead Pharmaceuticals will participate 2024 Summer Series R&D Webinar: Obesity/Metabolic – ARO-INHBE2024-08-14T14:00:00
Arrowhead Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-08-08T16:30:00
Arrowhead Pharmaceuticals Inc Third Quarter Earnings Result for 20242024-08-08T00:00:00
Goldman Sachs 45th Annual Global Healthcare Conference2024-06-12T16:00:00
Jefferies Global Healthcare Conference2024-06-05T12:30:00
Liver-targeted therapeutic siRNAs against highly conserved yellow fever virus genomic sequences effectively limit infection and mortality in a hamster model2024-05-22T10:45:00
A lung-targeted therapeutic siRNA against highly conserved viral M1 mRNAs effectively limits highly pathogenic influenza A infection in mice2024-05-20T11:30:00
Lung-targeted RNAi molecules silence human TSLP expression in PCLS cultures and humanized mice and suppress pulmonary allergic inflammation2024-05-20T11:30:00
A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma2024-05-19T11:30:00
BofA Securities 2024 Healthcare Conference2024-05-16T08:40:00
2024 RBC Capital Markets Global Healthcare Conference2024-05-14T09:30:00
Arrowhead Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-05-09T16:30:00
Arrowhead Pharmaceuticals Inc Second Quarter Earnings Result for 20242024-05-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.